Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.

[1]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[2]  E. Perez,et al.  Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC , 2009, Breast Cancer Research and Treatment.

[3]  D. Dodwell,et al.  Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[4]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[5]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[7]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Perez,et al.  Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Perez,et al.  Aromatase inhibitors and bone loss. , 2006, Oncology.

[10]  J. Cuzick,et al.  Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[12]  Richard Eastell,et al.  Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. , 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[13]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[14]  P. Lønning,et al.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.

[15]  S. Boonen,et al.  Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.

[16]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[17]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[18]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[19]  C. Crandall.  Risedronate: a clinical review. , 2001, Archives of internal medicine.

[20]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[21]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[22]  R I Price,et al.  Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. , 1991, The New England journal of medicine.

[23]  C. Christiansen,et al.  Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. , 1987, The New England journal of medicine.

[24]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[25]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.